Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma

• Published in: BMC cancer Vol. 9; no. 1; p. 90
• Main Authors: Rosa, Fabíola E, Silveira, Sara M, Silveira, Cássia G T, Bérgamo, Nádia A, Neto, Francisco A Moraes, Domingues, Maria A C, Soares, Fernando A, Caldeira, José R F, Rogatto, Silvia R
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 23.03.2009; BioMed Central; BMC
• Subjects: Adult; Aged; Aged, 80 and over; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Diagnosis; Drug therapy; Female; Gene Amplification; Gene Dosage; Genetic aspects; Health aspects; Humans; Immunohistochemistry; In situ hybridization; In Situ Hybridization, Fluorescence - methods; Middle Aged; Neoplasm Staging; Polymerase chain reaction; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction - methods; Brazil

HER-2 gene testing has become an integral part of breast cancer patient diagnosis. The most commonly used assay in the clinical setting for evaluating HER-2 status is immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). These procedures permit correlation between HER-2 expressio...